US counterplan fails – Common rule checks innovation
Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)
The public exposure to several unethical experiments conducted in the United States and abroad led to the development of the Belmont Report (Smith and Master 2014). The Belmont Report underscores three fundamental tenets of research ethics: respect for persons, beneficence, and justice. Heavily influenced by the Belmont Report, the Common Rule (45 CFR 46) is an overarching set of regulations that aims to protect human subjects participating in research. Fifteen Federal agencies, including the DoD, have signed on to the Common Rule in 1991 with the purpose of promoting uniformity in how research involving humans is governed. The Common Rule has several subparts providing additional protections for vulnerable populations such as pregnant women, human fetuses and neonates, prisoners, and children (Smith and Master 2014). Provisions within the Common Rule include the composition and processes of institutional review boards and informed consent among others. The Common Rule was revised in January 2017 with an effective date for July 19, 2018.
Prior to the Common Rule era, military research involving human subjects was largely accelerated due to the use of poison gas during World War I and the subsequent development of a chemical warfare defence programme. During the time between the two world wars, it is estimated that approximately 60,000 U.S. service members were experimentally exposed to Mustard gas and Lewistite (Brown 2009). Although the programme ramped down significantly following the end of World War II, military scientists continued research and development to seek out more effective compounds that could act as nerve agents, incapacitating compounds, and psychoactive agents. An additional 6,720 service members are estimated to have participated in experiments to test these agents from 1955 to 1979 (Brown 2009). Experiments were conducted under a shroud of secrecy but were still based on Nuremberg and Helsinki guidance and emphasized that participation was voluntary (Brown 2009). Since that time, military research involving service members has involved everything from human performance, feeding and nutrition, military medicine, and social behavioural interactions. Department of Defense human protections oversight has evolved to ensure more transparency, accountability, and greater protection for service members and civilians participating in DoD sponsored research.
Each Federal agency has also adopted protections in their instance of the rule to protect specific populations known to participate in research they sponsor. The DoD makes additional provisions for research involving service members. Due to the superior-subordinate relationship that exists in the military, DoD research policy provides additional protections to minimize command influence, to ensure that each individual gives informed consent in advance, and to limit waivers of informed consent (Amoroso and Wenger 2003). Furthermore, 10 United States Code 980 (10 USC 980) requires that all human participants of DoD sponsored research be able to give consent in advance of the research unless such research is intended to directly benefit the participant, in which case consent may be obtained from a legal representative (Sec 980 2005). The DoD has developed instructions that delineate the implementation of the Common Rule and considerations regarding special protections for service members (DoDI 3216.02, 2002). The DoD has also agreed to comply with all civilian Food and Drug Administration (FDA) regulations regarding the development and use of new pharmaceuticals, including the requirement to obtain informed consent from human subjects participating in experimental drug and biologics trials.